摘要:
Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ2—, —CY2═CZ2—, —CY2Y3—CHZ2—, —S—, —O—, or the like; Y1, Y2, Y3, Z1 and Z2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z1 and Z2 may be independently a linker group that may combine with Ar2 and Ar1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate thereof; are disclosed.
摘要:
Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ2-, —CY2═CZ2-, —CY2Y3—CHZ2-, —S—, —O—, or the like; Y1, Y2, Y3, Z1 and Z2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z1 and Z2 may be independently a linker group that may combine with Ar2 and Ar1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate thereof; are disclosed.
摘要:
Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ2—, —CY2═CZ2—, —CY2Y3—CHZ2—, —S—, —O—, or the like; Y1, Y2, Y3, Z1 and Z2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z1 and Z2 may be independently a linker group that may combine with Ar2 and Ar1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate thereof; are disclosed.
摘要:
Pharmaceutical compositions for enhancing the expression of apoAI are provided, which are used as medicaments for treatment of cardiovascular diseases on the basis of improving the functions of HDL.Pharmaceutical compositions for enhancing the expression of apoAI which comprises a compound of formula (I): in which X1 and X1 are independently an aryl or heteroaryl that may be optionally substituted, a hydrogen, a halogen, or the like; ring A is a benzene ring or 6-membered aromatic heterocyclic ring containing 1 to 3 N atoms that may be optionally condensed with another aromatic ring; R1 to R4 are independently a hydrogen, a halogen, a lower alkyl, a lower alkoxy or the like; a prodrug thereof, a pharmaceutically acceptable salt or solvate of them are disclosed.
摘要翻译:提供了用于增强载脂蛋白A表达的药物组合物,其用于治疗心血管疾病的药物,其基础是改善HDL的功能。 用于增强载脂蛋白A表达的药物组合物,其包含式(I)化合物:其中X1和X1独立地为可任意取代的芳基或杂芳基,氢,卤素等; 环A是含有1〜3个N原子的苯环或6元芳族杂环,其可以任选地与另一个芳环稠合; R 1至R 4独立地为氢,卤素,低级烷基,低级烷氧基等; 公开了其前药,药学上可接受的盐或溶剂合物。
摘要:
A hot-rolled steel sheet satisfies that average pole density of orientation group of {100} to {223} is 1.0 to 5.0 and pole density of crystal orientation {332} is 1.0 to 4.0. Moreover, the hot-rolled steel sheet includes, as a metallographic structure, by area %, ferrite and bainite of 30% to 99% in total and martensite of 1% to 70%. Moreover, the hot-rolled steel sheet satisfies following Expressions 1 and 2 when area fraction of the martensite is defined as fM in unit of area %, average size of the martensite is defined as dia in unit of μm, average distance between the martensite is defined as dis in unit of μm, and tensile strength of the steel sheet is defined as TS in unit of MPa. dia≦13 μm (Expression 1) TS/fM×dis/dia≧500 (Expression 2)
摘要:
The present invention provides a method for manufacturing a hot stamped body, the method including: a hot-rolling step; a coiling step; a cold-rolling step; a continuous annealing step; and a hot stamping step, in which the continuous annealing step includes a heating step of heating the cold-rolled steel sheet to a temperature range of equal to or higher than Ac1° C. and lower than Ac3° C.; a cooling step of cooling the heated cold-rolled steel sheet from the highest heating temperature to 660° C. at a cooling rate of equal to or less than 10° C./s; and a holding step of holding the cooled cold-rolled steel sheet in a temperature range of 550° C. to 660° C. for one minute to 10 minutes.
摘要:
This high-strength steel sheet includes: in terms of percent by mass, 0.03 to 0.10% of C; 0.01 to 1.5% of Si; 1.0 to 2.5% of Mn; 0.1% or less of P; 0.02% or less of S; 0.01 to 1.2% of Al; 0.06 to 0.15% of Ti; and 0.01% or less of N; and contains as the balance, iron and inevitable impurities, wherein a tensile strength is in a range of 590 MPa or more, and a ratio between the tensile strength and a yield strength is in a range of 0.80 or more, a microstructure includes bainite at an area ratio of 40% or more and the balance being either one or both of ferrite and martensite, a density of Ti(C,N) precipitates having sizes of 10 nm or smaller is in a range of 1010 precipitates/mm3 or more, and a ratio (Hvs/Hvc) of a hardness (Hvs) at a depth of 20 μm from a surface to a hardness (Hvc) at a center of a sheet thickness is in a range of 0.85 or more.
摘要:
This high-strength steel sheet includes: in terms of percent by mass, 0.03 to 0.10% of C; 0.01 to 1.5% of Si; 1.0 to 2.5% of Mn; 0.1% or less of P; 0.02% or less of S; 0.01 to 1.2% of Al; 0.06 to 0.15% of Ti; and 0.01% or less of N; and contains as the balance, iron and inevitable impurities, wherein a tensile strength is in a range of 590 MPa or more, and a ratio between the tensile strength and a yield strength is in a range of 0.80 or more, a microstructure includes bainite at an area ratio of 40% or more and the balance being either one or both of ferrite and martensite, a density of Ti(C,N) precipitates having sizes of 10 nm or smaller is in a range of 1010 precipitates/mm3 or more, and a ratio (Hvs/Hvc) of a hardness (Hvs) at a depth of 10 μm from a surface to a hardness (Hvc) at a center of a sheet thickness is in a range of 0.85 or more.
摘要:
A cold-rolled steel sheet satisfies that an average pole density of an orientation group of {100} to {223} is 1.0 to 5.0, a pole density of a crystal orientation {332} is 1.0 to 4.0, a Lankford-value rC in a direction perpendicular to a rolling direction is 0.70 to 1.50, and a Lankford-value r30 in a direction making an angle of 30° with the rolling direction is 0.70 to 1.50. Moreover, the cold-rolled steel sheet includes, as a metallographic structure, by area %, a ferrite and a bainite of 30% to 99% in total and a martensite of 1% to 70%.
摘要:
The present invention provides a method for manufacturing a hot stamped body having a vertical wall, the method including: a hot-rolling step; a coiling step; a cold-rolling step; a continuous annealing step; and a hot stamping step, in which the continuous annealing step includes a heating step of heating the cold-rolled steel sheet to a temperature range of equal to or higher than Ac1° C. and lower than Ac3° C.; a cooling step of cooling the heated cold-rolled steel sheet from the highest heating temperature to 660° C. at a cooling rate of equal to or less than 10° C./s; and a holding step of holding the cooled cold-rolled steel sheet in a temperature range of 550° C. to 660° C. for one minute to 10 minutes.